Lung Disease Associated with the IVS8 5T Allele of the CFTR Gene

Size: px
Start display at page:

Download "Lung Disease Associated with the IVS8 5T Allele of the CFTR Gene"

Transcription

1 Lung Disease Associated with the IVS8 5T Allele of the CFTR Gene PEADAR G. NOONE, CHARLES A. PUE, ZHAOQING ZHOU, KENNETH J. FRIEDMAN, EMMA L. WAKELING, MUTTIAH GANESHANANTHAN, RICHARD H. SIMON, LAWRENCE M. SILVERMAN, and MICHAEL R. KNOWLES Cystic Fibrosis/Pulmonary Research and Treatment Center, Departments of Medicine, and Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Institute of Child Health, University of London, London, United Kingdom; Pinnacle Health at Polyclinic Hospital, Harrisburg, Pennsylvania; and University of Michigan, Ann Arbor, Michigan Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) gene. The 5T allele in intron 8 (IVS8) causes abnormal splicing in the CFTR gene, and is associated with lung disease when it occurs in cis with a missense mutation in the CFTR gene, R117H. However, the 5T variant alone has not been reported to cause lung disease. We describe two adult female patients with CF-like lung disease associated with the 5T allele. One patient s genotype is 5T-TG12-M470V/5T-TG12-M470V, and the other is F508/5T-TG12-M470V; full sequencing of the CFTR gene revealed no other mutation on the same allele as the 5T variant. The levels of full-length CFTR mrna in respiratory epithelia were very low in these patients (11 and 6%, respectively, of total CFTR mrna expression). Both patients had defective CFTR-mediated chloride conductance in the sweat ductal and/or acinar epithelia (sweat chloride, mmol/l, mean SEM: [n 8 samples] and [n 6 samples]) and airway epithelia (mv, mean SEM CFTR-mediated Cl conductance of [n 5 studies] and [n 4 studies]). These data suggest that the 5T polythymidine tract sequence on specific haplotype backgrounds (TG12 and M470V) may cause a low level of full-length functional CFTR protein and CF-like lung disease. The cystic fibrosis (CF) transmembrane conductance regulator (CFTR) gene consists of 250 kb of genomic sequence, with 27 exons (1), with over 900 CFTR mutations associated with clinical disease described (see cftr/) (2). Phenotypic expression of CF varies from severe, progressive pulmonary disease with pancreatic insufficiency (PI), to mild pulmonary disease with pancreatic sufficiency (PS) depending upon the site of the mutation and the relative impairment of the function of the CFTR chloride channel (2). Single-organ disease, such as congenital bilateral absence of the vas deferens (CBAVD) in males without lung disease, is associated with mutations in the CFTR gene, including the 5T allele of the polythimidine tract in the intron 8 (IVS8) (3, 4). Of the three alleles that have been identified in IVS8 (5T, 7T, and 9T), the 9T allele is associated with the most efficient usage of the intron 8 splice acceptor site (5). This efficiency decreases with shorter polythymidine tracts (5T and 7T), which results in a lower than normal level of full-length CFTR mrna and presumably a decrease in mature, functional CFTR protein. Previously, the 5T and 7T alleles have been described as polymorphisms responsible for the variable expression of the mild CFTR gene mutation R117H. For example, an R117Hbearing allele in cis with a 7T allele may result in CBAVD, (Received in original form March 29, 2000 and in revised form July 14, 2000) Supported in part by grants from the National Institutes of Health (NIH 34332, RR00046) and The Cystic Fibrosis Foundation (CFF L543). Correspondence and requests for reprints should be addressed to Peadar G. Noone, Pulmonary Division, CB #7248, The University of North Carolina at Chapel Hill, Chapel Hill, NC pnoone@med.unc.edu Am J Respir Crit Care Med Vol 162. pp , 2000 Internet address: whereas when associated with the 5T allele, the phenotypic expression may be associated with mild CF lung disease and pancreatic sufficiency. Other haplotype backgrounds, such as the TG12 sequence and the M470V polymorphism, may influence CFTR splicing and function (6, 7). This report describes two female patients with lung disease associated with the 5T sequence, with no other CF gene mutations on the same allele. To address the link between the 5T allele and disease at the molecular, cellular, and organ level, we performed detailed evaluations on both patients. METHODS Patients Two female patients were referred to the University of North Carolina Hospitals because of unexplained chronic respiratory symptoms. We performed standard medical evaluations, including spirometry, radiographs of the chest, and tests of digestive function. All studies were carried out under the auspices of the Committee for the Protection on the Rights of Human Subjects at UNC-Chapel Hill. Evaluation of CFTR Physiological Function in Airway Epithelia Bilateral sweat chloride testing was performed in both patients, including tests at referring hospitals and at UNC (8, 9). We tested sweat acinar function with an intradermal injection of isoproterenol and aminophylline (to stimulate camp-mediated sweating) and atropine (to block sweating via cholinergic mechanisms) (10, 11). Non-CF individuals sweat briskly in response to the mixture, whereas CF patients do not sweat because of abnormalities of the camp CFTR-mediated pathway. Ion transport physiology across airway epithelia was tested by performing nasal potential difference (PD) measurements in both patients (12). Molecular Studies Detection of CF mutations and IVS8 polythimidine tract polymorphisms. DNA was extracted from peripheral lymphocytes, and 32 CFcausing mutations, and 5T, 7T, and 9T alleles were tested as described (13 15). Additional mutations were sought by sequencing of each exon of the CFTR gene including the flanking splice sites after amplification by polymerase chain reaction (PCR). PCR products were purified (QIAquick PCR purification kit; Qiagen, Valencia, CA) and sequenced (BigDye Terminator Cycle Sequencing kit; Perkin-Elmer, Applied Biosystem, Foster City, CA). Fluorescence-labeled DNA fragments were analyzed on an ABI Prism 310 (Perkin Elmer). Nasal scrape biopsy and RNA extraction. Airway epithelial cells were obtained by scraping the inferior surface of the inferior turbinate with a plastic curette (Rhinoprobe, Arlington Scientific Inc., Arlington, TX). The cells were immediately washed in F12 medium, and lysed in 1 ml of TRIzol reagent for RNA extraction (GIBCO BRL, Bethesda, MD). cdna synthesis. The first strand of cdna was synthesized by using oligo(dt) and SuperScript II RNase H reverse transcriptase (GIBCO BRL) according to the manufacturer s protocol. Approximately 1 g of the total nasal epithelial RNA was used in a 20 l reaction. The reaction mixture was incubated at 42 C for 1 h.

2 1920 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL Quantitation of CFTR mrna Expression by Hot PCR To estimate the relative amounts of the normally spliced CFTR mrna (exon 9 ) expressed from the non- F508 allele, the CFTR cdna was selectively amplified using an allele-specific reverse primer located in exon 10 (1669R: 5 -CATAGGAAACACCAAAGATGA) and a forward primer located in exon 6a (781F: 5 -GAGTTGTTACAGGCG- TCTGCCTTC). A 50- l reaction mix of each sample included 5 l of 10 buffer (200 mm Tris HCl, 500 mm KCl, ph 8.4; GIBCO BRL), 2 l of 50 mm MgCl 2, 0.25 l of 5 U/ l Taq DNA polymerase (GIBCO BRL), 1 l of dntp mix (2.5 mm of each), 1 l of [ - 32 P]dCTP (3,000 Ci/mmol; ICN), 2 l of each primer (10 pmol/ l), 2 l of cdna, 5 l of 60% sucrose with 0.04% Cresol Red (Sigma), and 30 l of H 2 O. The PCR mix was then divided into two tubes equally (25 l each) for a 24-cycle reaction and a 27-cycle reaction. Of the end PCR products 20 l was subjected to electrophoresis on a 6% acrylamide gel (29:1) containing 1 TBE and 4% glycerol. The gel was vacuum dried and exposed to the film (Kodak BioMax MR film, Rochester, NY) at 70 C for 2 h to overnight. The exon 9 and exon 9 fragments on the dried gel were quantified by using a PhosphoImager (Molecular Dynamics, Sunnyvale, CA). The molar ratio of the exon 9 fragment (889 bp) and the exon 9 fragment (706 bp) was adjusted in the final calculation according to the fragment size. Analysis of DNA Polymorphisms in or Near the CFTR Gene Extragenic loci, XV2c, KM-19, and JG3c, were evaluated as previously described (16, 17). Intragenic polymorphisms were examined mainly by DNA sequencing. Studies of Uniparental Disomy (UPD) for Chromosme 7 Methylation-specific PCR was used to evaluate patient 1 for uniparental disomy for chromosome 7. Bisulfite treatment of DNA and PCR were performed by methods described previously (18, 19). Both maternal and paternal allele-specific reactions were performed to evaluate parental inheritance. RESULTS Clinical Data (Table 1) Patient 1 (white female) reported frequent respiratory infections as an adolescent and young adult, undergoing sinus surgery on three occasions. Sinus and lower airway have been culture positive for mucoid and nonmucoid Pseudomonas aeruginosa, Alcaligenes xylosoxidans, Staphylococcus aureus, and Aspergillus flavus. A bronchoscopy (at age 46) showed normal airways, mucoid P. aeruginosa, and a positive smear (4+) and culture for Mycobacterium avium complex (MAC). She was treated with intravenous antipseudomonal antibiotics with improvement. She has only had one subsequent positive smear for MAC (January 2000). Recently, she has required intravenous antipseudomonal antibiotics 4 times per year. There is no family history of CF, and no consanguinity has been identified. The patient was small: her height was 145 cm (4 ft 9 in.) and her weight was 33 kg ( 73 lb). Bilateral crackles were noted. A high-resolution chest computed tomography (HRCT) showed diffuse bronchiectasis with a marked right upper and right lower lobe predominance. Images of the pancreas were normal, with no fatty replacement typical of CF. Sinus CT scans showed complete opacification of the sinuses. Lung function showed mild obstructive airways disease (FEV L, 76% predicted, and FVC 2 L, 75%, respectively). Serum trypsinogen was normal (34 ng/ml, normal 10 57). A 3-d stool fat quantitation test showed normal fat absorption (12% of stool was excreted as fat). Other causes of bronchiectasis were excluded: allergic bronchopulmonary aspergillosis (no history of asthma [serum IgE; 72 IU/ml, normal range 0 158], and negative precipitins to A. fumigatus), primary ciliary dyskinesia (normal ciliary ultrastructure and function), hypogammaglobulinemia (normal immunoglobulin and subclass levels), and serum 1 -antitrypsin levels were normal (139 mg/dl, normal ). Patient 2 (white female) experienced recurrent respiratory infections during adolescence and adulthood, with a cough productive of purulent sputum, and sinus infections. Sputum and sinus samples have repeatedly cultured mucoid and nonmucoid Pseudomonas aeruginosa. She has no symptoms of pancreatic insufficiency. Her family history is strongly positive for CF: a daughter had CF (the husband is heterozygote for F508), and two first cousins had CF. On examination, the nasal mucosa was inflamed, with crackles audible at the left lung base. The chest CT scan showed patchy densities in the left upper and right middle lobe, and both lower lobes. Sinus CT scans show opacification of the maxillary sinuses. Lung function was normal: FEV (115% predicted), FVC 3.77 (125%). Blood work showed normal serum trypsinogen (34 ng/dl, normal 10 57) and IgE levels (104 IU/dl, normal ). Other causes of chronic lung disease were excluded, such as primary ciliary dyskinesia (normal ciliary activity and ultrastructure) and hypogammaglobulinemia (normal serum immunoglobulins). In Vivo Respiratory Epithelial Cell and Sweat Gland Physiological Data (Table 2) Sweat chloride results (bilateral tests) for patient 1 demonstrated borderline values on three separate occasions (40 and TABLE 1 CLINICAL DATA FOR TWO PATIENTS WITH CHRONIC LUNG AND SINUS DISEASE ASSOCIATED WITH THE IVS8 5T ALLELE IN THE CFTR GENE Patient 1 (5T-TG12-M470V homozygote) Patient 2 ( F508/5T-TG12-M470V) Age at diagnosis Smoker Nonsmoker Nonsmoker Respiratory symptoms Cough/sputum since childhood Several pneumonias in childhood Cough/sputum since age 60 Sinus symptoms Since age 23 Since age 50 CXR/CT Bilateral right upper lobe predominant Right middle lobe infiltrate/nodule bronchiectasis Upper lobe scarring Sinus radiographs Opacification of maxillary, sphenoid, and Opacification of maxillary sinuses, frontal sinuses with air fluid levels mucosal thickening of ethmoid sinuses Sputum bacteriology P. aeruginosa (mucoid and nonmucoid), P. aeruginosa (mucoid) S. aureus, Mycobacterium avium complex FEV 1, L (% pred) 1.7 (76%) 2.8 (115%) Definition of abbreviation: CFTR cystic fibrosis transmembrane regulator.

3 Noone, Pue, Zhou, et al.: The 5T Variant in Intron 8 Causes CF-type Lung Disease 1921 TABLE 2 SWEAT CHLORIDE CONCENTRATIONS (meq/l), SWEAT SECRETION TESTS (see text), AND NASAL EPITHELIAL PD DATA FROM THE TWO PATIENTS WITH ABNORMAL IVS8 CFTR ALLELES* Sweat Chloride (meq/l) Sweat Stimulation Mean Basal /Maximal PD (mv) Amiloride Response (% inhibition) CFTR-Mediated Cl Conductance (mv) UTP Response (mv) Patient NS 24.8/ Patient 2** NS 31.6/ Definition of abbreviations: CFTR cystic fibrosis transmembrane regulator; PD potential difference; UTP uridine triphosphate. * CFTR-mediated Cl conductance is calculated as the sum of the response to Cl -free solution and isoproterenol. Normal range 60 mmol/l. Mean basal PD from five sites under the turbinate, normal range 30 mv. Results of three studies in patient 1, two studies in patient 2. Delta PD, normal values mv, classic (pancreatic insufficient) CF values mv, CF with pancreatic sufficient mutations Mean SEM data derived from four separate bilateral sweat tests and five separate PD studies. NS no sweating visible after stimulation of CFTR-mediated sweat acinar epithelia. ** Mean SEM data derived from three separate bilateral sweat tests and four separate PD studies. 51, 40 and 53, and 51 and 48 mmol/l) and normal values (18 and 19 mmol/l) on a fourth occasion. Sweat chloride testing in patient 2 was abnormal on three occasions: 86 and 83 mmol/l in 1995, 85 and 88 mmol/l, and 70 mmol/l and 68 mmol/l in In both patients, there was complete absence of sweating in response to the intradermal injection of aminophylline, atropine, and ioproterenol, signifying defective sweat acinar CFTR function. The mean basal PD for both patients was normal, although patient 2 had a raised (CF-like) maximal PD of 56.5 mv. The mean CFTR-mediated Cl conductance (mv) for both patients was reduced below normal, though not as low as patients with pancreatic insufficient CF (see Table 2). The mean CFTR-mediated Cl conductance for both patients falls into the range of pancreatic sufficient CF, and indicates reduced CFTR function. An adequate chloride conductance was present in response to the triphosphate nucleotide UTP in both patients (ranging from 5.5 to 26.5 mv in patient 1 and 4 to 11 mv in patient 2) suggesting normal epithelial integrity for the studies. Molecular Data: CFTR Genotyping Initially, 32 CF-causing mutations and the polythymidine polymorphism in intron 8 (5T, 7T, and 9T) were tested in the two patients (14). Patient 1 was found to be homozygous for the 5T allele. Patient 2 was found to be heterozygous for the F508 mutation and heterozygous for the 5T and 9T alleles in intron 8. Because F508 is almost always found in cis to a 9T, the 5T allele may be assigned to the opposite chromosome (20). Thus, patient 2 is a compound heterozygote for two abnormalities in the CFTR gene, one of which is the 5T allele alone. No additional mutations were detected after sequencing all 27 exons of the CFTR gene including the flanking splice sites. Given the reported influence of the number of TG repeats (TG10, 11, 12, 13) adjacent to the poly-t tract to reduce the splicing efficiency of full-length CFTR, both patients were tested for the polymorphic TG sequence (6, 7). Both patients were tested for the M470V polymorphism, as the 5T allele has been reported in preferential association with this exon 10 sequence polymorphism (21). This latter variant, although not linked with any pathology, is associated with a reduced ( 60%) chloride channel capacity (6). Patient 1 is homozygous for the M470V polymorphism and the TG12 repeat sequence, whereas patient 2 has M470V and the TG12 sequence in cis with the 5T allele. In addition, RT-PCR products encompassing all 27 exons were examined for the presence of abnormal splicing. No aberrant fragments, other than the exon 9 fragment, were seen, suggesting no intronic splice mutations. Quantitative Analysis of CFTR mrna Two CFTR mrna transcripts result from variants in the poly-t tract: exon 9 and exon 9 (22). The exon 9 transcript is the normal full-length CFTR mrna, whereas the exon 9 is the aberrant transcript. We estimated the levels of normally spliced CFTR mrna (exon 9 ) expressed from the 5T alleles in nasal epithelial cells. We compared the two patients with healthy F508 carriers with either a 7T or a 9T on the other allele (n 4), and healthy control subjects with no mutations in CFTR (n 9, 7T/7T) (Figure 1). We considered 7T/7T individuals as the best control subjects for the study, as this variant comprises the largest proportion of individuals in Figure 1. Quantitative estimation of CFTR mrna in two patients with the 5T variant in the CFTR gene as compared with healthy control subjects. (A) Autoradiograph of a dried gel showing the 32 P-labeled RT- PCR products of the exon 9 and exon 9 CFTR mrna expressed from the non- F508 alleles in the patients and control subjects. The quantitative estimation of CFTR mrna represent patient 1 (5T/5T, lane 1) and patient 2 ( F508/5T, lane 2) and healthy carriers of F508/7T (lanes 3 and 4) and F508/9T (lanes 5 and 6). (B) Relative levels of total functional CFTR mrna derived from the RT-PCR autoradiograph above (lanes 1 6). Each column reflects the relative amount of functional CFTR mrna (exon 9 mrna expressed from the non- F508 allele) in patient 1 (5T/5T; 11%), patient 2 (5T/ F508; 6%), four healthy carriers of F508 (7T/ F508 and 9T/ F508; 41 48%), and nine healthy normal subjects with no CFTR mutations (n 9, 7T/7T; % SEM: , autoradiograph not shown).

4 1922 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL the general populations ( 70%) (20). To exclude the CFTR mrna expressed from the F508 allele in patient 2, allelespecific PCR was performed. Only the cdna representing the CFTR mrna expressed from the non- F508 allele was amplified and the exon 9 and exon 9 products were analyzed for quantification. The levels of normal full-length CFTR mrna (exon 9 ) expressed from the 5T alleles were severely reduced in the patients as compared with the mrna expressed from the 7T or 9T alleles in the control group (Figure 1). The relative amount of the exon 9 CFTR mrna in patient 1 (5T/5T) was also compared with healthy individuals homozygous for 7T or 9T by Southern hybridization (data not shown). The entire coding region of the CFTR cdna (4.5 kb) was amplified to minimize unequal amplification due to the size difference (183 bp) between the exon 9 and exon 9 fragments. The results were compatible with the quantitative analysis depicted in Figure 1. In patient 1, the exon 9 CFTR mrna associated with the 5T alleles was 11 12% of total. Finally, to exclude the possibility of mutations in the promoter regions, we compared the amounts of CFTR mrna expressed from the 5, 7, and 9T alleles relative to the F508 allele. The amount of CFTR mrna from the 5T allele relative to the F508 allele was comparable with the amounts from the 7T and 9T alleles in the healthy F508 carriers (data not shown). This suggests no mutations in the promoter region, as there was no change in CFTR mrna expression arising from the 5T allele in patient 2. Haplotype Analysis and Uniparental Disomy Studies of Patient 1 Patient 1 is of short stature, thus the possibility is raised of a variant of Russell Silver Syndrome, a condition associated with maternal uniparental disomy (UPD) for chromosome 7, which is the cytogenetic basis for CF in individuals who received both copies of their mutation-bearing chromosomes from one parent (23 25). Because no parental or sibling DNA was available because all were deceased, evidence for UPD 7 was sought by methylation-sensitive PCR of the DNA of patient 1 to distinguish the differentially methylated parental alleles of the imprinted gene, MEST, which, along with CFTR, maps to 7q32. Both maternal and paternal alleles were detected in patient 1, suggesting that she does not have UPD 7 (data not shown). DISCUSSION This report provides evidence for a link between the 5T allele of the polythymidine tract of intron 8, occurring with the TG12 and the M470V haplotype background, and low-level expression of full length of CFTR mrna, defective CFTRmediated Cl conductance, and CF-type lung disease. At a clinical level, both of the patients in this report demonstrate characteristics consistent with a mild variant of cystic fibrosis. Each patient had defective CFTR function on sweat testing and sweat gland stimulation and reduced CFTR-mediated Cl conductance across respiratory epithelia (12). There were no other established mutations in CFTR in cis to the 5T allele after full sequencing of the CFTR gene. This suggests that the 5T allele, perhaps with influence from the TG12 repeat sequence and the M470V polymorphism, is responsible for the defective CFTR expression and function in these patients, leading to clinical disease. To strengthen this hypothesis, the expression of full-length CFTR mrna (exon 9 ) in respiratory epithelia was found to be reduced as compared with healthy individuals. Other reports have suggested a link between the 5T allele and lung disease. Chillon and colleagues studied patients with CBAVD, and found three adults with CBAVD and mild lung disease who were compound heterozygotes for the F508 allele and the 5T allele (3). Three other (younger) patients were compound heterozygotes for E858X/5T and K710X/5T, with episodes of dehydration and abnormal sweat chlorides, but no other clinical features of CF. Unfortunately, other gene variant and CFTR expression data, and further clinical details, were not available for these six patients. In another report, the 5T allele was found to occur more frequently than expected in a population of patients with diffuse bronchiectasis of unknown origin (5/15, 31%) (26). None of these patients had CF as assessed by clinical and molecular methods. Therefore, the clinical spectrum of disease and sweat gland CFTR function of these previous reports differs from the patients in this report. Finally, Kerem and coworkers reported a series of patients with CF, variant CF, and chronic lung disease, and found that the incidence of the 5T variant was above that expected for the population (Jewish/Arab) (27). However, the patients had a very variable expression of disease, and the clinical and physiological data were gathered retrospectively from a number of centers. Interestingly, the three patients homozygous for the 5T variant did not have lung disease. These data suggested, at least on a population basis, that the 5T variant is associated with lung disease in some patients. Another clinical disease recently linked to mutations in the CFTR gene is idiopathic pancreatitis (28, 29). Although those published studies initially did not demonstrate an increase in the prevalence of the 5T allele in that population of patients with nonpulmonary disease, further analyses subsequently indicated a higher than expected incidence of 5T compound heterozygotes and homozygotes (30). Neither of the patients in this current report has a history of pancreatitis resembling those patients with CFTR-related pancreatitis. This may relate in part to different levels of CFTR expression, and the threshold level required for the presence or absence of pancreatic disease. Alternatively, it may relate to tissue-specific normal and abnormal splicing of CFTR mrna, or the influence of epigenetic or environmental factors. The cell physiological data from the patients in this report may provide insights into the relationship between CFTR defects and clinical expression of disease. Classic CF is associated with a high basal PD, and absent CFTR-mediated Cl conductance (12). Both of the patients in this report had basal PDs lower than classic CF, but higher than normal, though both had maximal PDs compatible with that seen in CF. CFTR-mediated Cl conductance, on the other hand, was reduced into the CF range in both patients (12). These PD values are similar to the pattern of bioelectric properties reported in men with CBAVD but no lung disease (31). It is unknown whether these young males with CBAVD may eventually develop CFTR-related lung disease. The observation in this report that both patients presented with relatively late onset disease is of particular interest, suggesting the more subtle way that this genetic abnormality influences the phenotypic expression of disease. The spectrum of disease in both patients resembles that of variant pancreatic sufficient CF, with an adult presentation and late diagnosis (32, 33). At a molecular level, the data are congruent with the notion that the length of the polythymidine tract bears a direct relationship to normal splicing of CFTR the 9T/9T allele resulting in the highest expression of normal CFTR mrna and the 5T/5T resulting in 15% of normal CFTR mrna (3). The threshold level of CFTR mrna expression is theorized to relate to the expression of disease, CBAVD being on the threshold because development of the vas deferens is exquisitely sensitive to reduced levels of CFTR function, and pancre-

5 Noone, Pue, Zhou, et al.: The 5T Variant in Intron 8 Causes CF-type Lung Disease 1923 atic insufficient CF is at the end of the spectrum with lowest levels of full-length CFTR. Subsequent data from Kerem and coworkers support this scenario: there is a direct correlation between disease expression and the level of correctly spliced mrna from the nose and the epididymis in 11 patients (9 males, 2 females) who carried at least one copy of the 5T variant (34). Patients with the least amount of correctly spliced CFTR mrna (6 14%) in respiratory epithelial cells had reduced lung function (FEV 1 80% predicted). It is important to note that the patients in this current report have, in addition to the 5T allele, the TG12 sequence on the same allele, which may further reduce the splicing efficiency of CFTR mrna, and the M470V polymorphism, which may reduce CFTR function at the apical membrane (6). In summary, variations in the IVS8 polythymidine tract alone, with the added influence of the TG12 repeat sequence and the M470V polymorphism, are associated with defective CFTR function in sweat glands and airway epithelia, and late onset lung disease resembling that seen in CF. Whereas the 5T allele has a frequency of 5% among white individuals, only 20% of these are in combination with the TG12 repeat as seen in the patients in this report. The other, shorter, TG sequences may not be associated with a pulmonary disease phenotype. Approximately 1 in 25 whites are carriers for a mutation in CFTR, and approximately 2% of white individuals are carriers of the 5T TG12 allele. That is, as many as 1:10,000 white individuals are homozygous for the 5T TG12 allele, and 1:2,500 may be a compound heterozygote for a mutation in CFTR and the 5T TG12 allele. Consequently, under the influence of modifier genes or accompanying polymorphisms, as many as 1:2,000 white individuals (or 115,000 of the U.S. population) may at some point in their lives be at risk for some or all of the many manifestations of this variant in the CFTR gene. If the 5T TG12 allele plays a role in the sinopulmonary and urogenital health of the number of people as these calculations suggest, it is essential that we understand fully the impact of this variant. Acknowledgment : The authors thank Vicky LeGrys, Ph.D., for helpful discussions regarding the sweat tests and interpretation. P. G. Noone and C. A. Pue contributed equally to this work. References 1. Stutts MJ, Boucher RC. Cystic fibrosis gene and functions of CFTR. In: Yankaskas JR, Knowles MR, editors. Cystic fibrosis in adults. Philadelphia: Lippincott-Raven; p Knowles MR, Friedman KJ, Silverman LM. Genetics, diagnosis and clinical phenotype. In: Yankaskas JR, Knowles MR, editors. Cystic fibrosis in adults. Philadelphia: Lippincott-Raven; p Chillon M, Casals T, Mercier B. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 1995;332: Anguiano A, Oates RD, Amos JA, Dean M, Gerrard B, Stewart C, Maher TA, White MB, Milunsky A. Congenital bilateral absence of the vas deferens: a primary genital form of cystic fibrosis. JAMA 1992; 267: Chu C-S, Trapnell BC, Curristin SM, Cutting GR, Crystal RG. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mrna. Nature Genet 1993;3: Cuppens H, Lin W, Jaspers M, Costes B, Teng H, Vankeerberghen A, Jorissen M, Droogmans G, Reynaert I, Goossens M, Nilius B, Cassiman JJ. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes: the polymorphic (TG)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest 1998;101: Niksic M, Romano M, Buratti E, Pagani F, Baralle FE. Functional analysis of cis-acting elements regulating the alternative splicing of human CFTR exon 9. Hum Mol Genet 1999;8: Gibson LE, Cooke RE. A test for the concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959;23: Quinton PM. The sweat gland. In: Yankaskas JR, Knowles MR, editors. Cystic fibrosis in adults. Philadelphia: Lippincott-Raven; p Sato K, Sato F. Defective beta adrenergic response of cystic fibrosis sweat glands in vivo and in vitro. J Clin Invest 1984;73: Behm JK, Hagiwara G, Lewiston NJ, Quinton PM, Wine JJ. Hyposecretion of beta-adrenergically induced sweating in cystic fibrosis heterozygotes. Pediatr Res 1987;22: Knowles MR, Paradiso AM, Boucher RC. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1995;6: Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1998; 16: Friedman KJ, Highsmith WE, Silverman LA. Detecting multiple cystic fibrosis mutations by polymerase chain reaction-mediated sitedirected mutagenesis. Clin Chem 1991;37: Friedman KJ, Heim RA, Knowles MR, Silverman LM. Rapid characterization of the variable length polythimidine tract in the cystic fibrosis (CFTR) gene: association of the 5T allele with selected CF mutations and its incidence in atypical sinopulmonary disease. Hum Mutat 1997; 10: Highsmith WE, Ching GL, Orr HT, Perry TR, Schald D, Farber R, Wagner K, Knowles MR, Warwick WJ, Silverman LM. Frequency of the delta Phe508 mutation and correlation with XV.2c/KM-19 haplotypes in an American population of cystic fibrosis patients: results of a collaborative study. Clin Chem 1990;36: Northrup H, Rosenbloom C, O Brien WE, Beaudet AL. Additional polymorphism for D7S8 linked to cystic fibrosis including detection by DNA amplification. Nucleic Acids Res 1989;17: Zeschnigk M, Lich C, Buiting K, Doerfler W, Horsthemke B. A single tube PCR test for the diagnosis of Angleman and Prader-Willi syndrome based on allelic methylation differences at the SNRPN locus. Eur J Hum Genet 1997;5: Riesewijk AM, Hu L, Schulz U, Tariverdian G, Hoglund P, Kere J, Ropers HH, Kalscheurer VM. Monoallelic expression of human PEG1/ MEST is paralleled by parent-specific methylation in fetuses. Genomics 1997;42: Kiesewetter S, Macek M Jr, Davis C, Curristin SM, Chu CS, Graham C, Shrimpton AE, Cashman SM, Tsiu LC, Mickle J. A mutation in CFTR produces different phenotypes depending on chromosomal background. Nature Genet 1993;5: de Meeus A, Guittard C, Desgeorges M, Carles S, D le J, Claustres M. Linkage disequilibrium between the M470V variant and the IVS8 polyt alleles of the CFTR gene in CBAVD. J Med Genet 1998;35: Chu CS, Trapnell BC, Curristin S, Cutting GR, Crystal RG. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mrna. Nature Genet 1993;3: Voss R, Ben-Simon E, Avital A, Godfrey S, Zlotogora J, Dagan J, Tikochinsky Y, Hillel J. Isodisomy of chromsosome 7 in a patient with cystic fibrosis: could uniparental disomy be common in humans? Am J Hum Genet 1989;45: Beaudet AL, Perciaccante RG, Cutting GR. Homozygous nonsense mutation causing cystic fibrosis with uniparental disomy. Am J Hum Genet 1991;48: Spence JE, Perciaccante RG, Greig GM, Willard HF, Ledbetter DH, Hejtmancik JF, Pollack MS, O Brien WE, Beaudet AL. Uniparental disomy as a mechanism for human genetic disease. Am J Hum Genet 1988;42: Pignatti PF, Bombieri C, Benetazzo M, Casartelli A, Trabetti E, Gile LS, Martinati LC, Boner AL, Luisetti M. CFTR gene variant ICS8-5T in disseminated bronchiectasis. Am J Hum Genet 1996;58: Kerem E, Rave-Harel N, Augarten A, Madgar I, Nissim-Rafinia M, Yahav Y, Goshen R, Bentur L, Rivlin J, Aviram M, Genem A, Chiba- Falek O, Kraemer MR, Simon A, Branski D, Kerem B. A cystic fibrosis transmembrane conductance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentations. Am J Respir Crit Care Med 1997;155: Cohn JA, Friedman KJ, Noone PG, Knowles MR, Silverman LM, Jowell PS. Relations between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 1998;339: Sharer N, Schwarz M, Malone G, Howarth A, Painter J, Super M, Braganza J. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 1998;339: Noone PG, Zhou Z, Pace RG, Silverman LM, Knowles MR, Cohn JA. Molecular, cell physiologic and clinical characteristics of patients with

6 1924 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL idiopathic pancreatitis with and without mutations in the CFTR gene. Pediatr Pulmonol 1999; (Suppl 19): Osborne LR, Lynch M, Middleton PG, Alton EWFW, Geddes DM, Pryor JP, Hodson ME, Santis GK. Nasal epithelial ion transport and genetic analysis of infertile men with congenital absence of the vas deferens. Hum Mol Genet 1993;2: Knowles MR, Barnett TB, McConkie-Rosell A, Sawyer C, Kahler CG. Mild cystic fibrosis in a consanguineous family. Ann Intern Med 1989; 110: Highsmith WE, Burch LH, Zhou Z, Knowles MR. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 1995;331: Rave-Harel N, Kerem E, Nissim-Rafinia M, Madjar I, Goshen R, Augarten A, Rahat A, Hurwitz A, Darvasi A, Kerem B. The molecular basis of partial penetrance of splicing mutations in cystic fibrosis. Am J Hum Genet 1997;60:87 94.

Review CFTR-opathies : disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations Peadar G Noone and Michael R Knowles

Review CFTR-opathies : disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations Peadar G Noone and Michael R Knowles Review CFTR-opathies : disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations Peadar G Noone and Michael R Knowles Pulmonary Research and Treatment Center, Department

More information

RELATION BETWEEN MUTATIONS OF THE CYSTIC FIBROSIS GENE AND IDIOPATHIC PANCREATITIS

RELATION BETWEEN MUTATIONS OF THE CYSTIC FIBROSIS GENE AND IDIOPATHIC PANCREATITIS RELATION BETWEEN MUTATIONS OF THE CYSTIC FIBROSIS GENE AND IDIOPATHIC PANCREATITIS RELATION BETWEEN MUTATIONS OF THE CYSTIC FIBROSIS GENE AND IDIOPATHIC PANCREATITIS JONATHAN A. COHN, M.D., KENNETH J.

More information

THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)

THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210. Vertex and the Vertex triangle logo are registered trademarks for Vertex

More information

Evaluation of Patients with Diffuse Bronchiectasis

Evaluation of Patients with Diffuse Bronchiectasis Evaluation of Patients with Diffuse Bronchiectasis Dr. Patricia Eshaghian, MD Assistant Clinical Professor of Medicine Director, UCLA Adult Cystic Fibrosis Affiliate Program UCLA Division of Pulmonary

More information

Mutations of the Cystic Fibrosis Gene and Intermediate Sweat Chloride Levels in Children

Mutations of the Cystic Fibrosis Gene and Intermediate Sweat Chloride Levels in Children Mutations of the Cystic Fibrosis Gene and Intermediate Sweat Chloride Levels in Children PATRICK LEBECQUE, TERESINHA LEAL, CHRISTIANE DE BOECK, MARTINE JASPERS, HARRY CUPPENS, and JEAN-JACQUES CASSIMAN

More information

A review of Cystic Fibrosis

A review of Cystic Fibrosis A review of Cystic Fibrosis Jennifer Landry md F.R.C.P.(C) Pulmonary & Critical Care Medicine McGill University Health Center Cystic Fibrosis One of the most common lethal inherited AR disorders in the

More information

"Management and Treatment of Patients with Cystic fibrosis (CF)

Management and Treatment of Patients with Cystic fibrosis (CF) "Management and Treatment of Patients with Cystic fibrosis (CF) Dr. Malena Cohen-Cymberknoh Pediatric Pulmonology and CF Center Hadassah Hebrew-University Medical Center Jerusalem, Israel Afula, March

More information

Cystic Fibrosis. Jennifer McDaniel, BS, RRT-NPS

Cystic Fibrosis. Jennifer McDaniel, BS, RRT-NPS Cystic Fibrosis Jennifer McDaniel, BS, RRT-NPS Overview Cystic fibrosis is the most common fatal, inherited disease in the U. S. CF results from a defective autosomal recessive gene One copy of gene =

More information

Bronchiectasis in Adults - Suspected

Bronchiectasis in Adults - Suspected Bronchiectasis in Adults - Suspected Clinical symptoms which may indicate bronchiectasis for patients Take full respiratory history including presenting symptoms, past medical & family history Factors

More information

A Quick Guide to the. I507del. Mutation CFTR SCIENCE

A Quick Guide to the. I507del. Mutation CFTR SCIENCE A Quick Guide to the I507del Mutation CFTR SCIENCE 2016 Vertex Pharmaceuticals Incorporated VXR-HQ-02-00045a(1) 03/2016 Loss of CFTR activity is the underlying cause of cystic fibrosis (CF) 1 Spectrum

More information

VARIANT CYSTIC FIBROSIS VARIANT CYSTIC FIBROSIS PHENOTYPES IN THE ABSENCE OF CFTR MUTATIONS. Patient Population

VARIANT CYSTIC FIBROSIS VARIANT CYSTIC FIBROSIS PHENOTYPES IN THE ABSENCE OF CFTR MUTATIONS. Patient Population VARIANT CYSTIC FIBROSIS PHENOTYPES IN THE ABSENCE OF CFTR MUTATIONS JOSHUA D. GROMAN, M.S., MICHELLE E. MEYER, M.S., ROBERT W. WILMOTT, M.D., PAMELA L. ZEITLIN, M.D., PH.D., AND GARRY R. CUTTING, M.D.

More information

Bronchiectasis: An Imaging Approach

Bronchiectasis: An Imaging Approach Bronchiectasis: An Imaging Approach Travis S Henry, MD Associate Professor of Clinical Radiology Cardiac and Pulmonary Imaging Section University of California, San Francisco Large Middle Small 1 Bronchiectasis

More information

CYSTIC FIBROSIS OBJECTIVES NO CONFLICT OF INTEREST TO DISCLOSE

CYSTIC FIBROSIS OBJECTIVES NO CONFLICT OF INTEREST TO DISCLOSE CYSTIC FIBROSIS Madhu Pendurthi MD MPH Staff Physician, Mercy Hospital Springfield, MO NO CONFLICT OF INTEREST TO DISCLOSE OBJECTIVES Epidemiology of Cystic Fibrosis (CF) Genetic basis and pathophysiology

More information

Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in Asians with chronic pulmonary disease: A pilot study B

Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in Asians with chronic pulmonary disease: A pilot study B Journal of Cystic Fibrosis 5 (2006) 159 164 www.elsevier.com/locate/jcf Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in Asians with chronic pulmonary disease: A pilot study

More information

A Cystic Fibrosis Transmembrane Conductance Regulator Splice Variant with Partial Penetrance Associated with Variable Cystic Fibrosis Presentations

A Cystic Fibrosis Transmembrane Conductance Regulator Splice Variant with Partial Penetrance Associated with Variable Cystic Fibrosis Presentations A Cystic Fibrosis Transmembrane Conductance Regulator Splice Variant with Partial Penetrance Associated with Variable Cystic Fibrosis Presentations EITAN KEREM, NAAMA RAVE-HAREL, ARIE AUGARTEN, IGAL MADGAR,

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Moss RB, Flume PA, Elborn JS, et al, on behalf

More information

Cystic fibrosis and survival to 40 years: a study of cystic fibrosis transmembrane conductance regulator function

Cystic fibrosis and survival to 40 years: a study of cystic fibrosis transmembrane conductance regulator function Eur Respir J 2011; 37: 1076 1082 DOI: 10.1183/09031936.00079010 CopyrightßERS 2011 Cystic fibrosis and survival to 40 years: a study of cystic fibrosis transmembrane conductance regulator function N.J.

More information

Cystic fibrosis: hitting the target

Cystic fibrosis: hitting the target Cystic fibrosis: hitting the target Heartland Collaborative Annual Meeting Friday, October 5, 2012 Thomas Ferkol MD 1938 1953 Cystic fibrosis: a historical timeline Cystic fibrosis (CF) of the pancreas

More information

The pathogenic consequences of a single mutated CFTR gene

The pathogenic consequences of a single mutated CFTR gene Thorax 1999;54(Suppl 2):S19 S23 S19 The pathogenic consequences of a single mutated CFTR gene Uta Griesenbach, Duncan M Geddes, Eric W F W Alton Department of Gene Therapy, Imperial College at the National

More information

THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)

THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210. Vertex and the Vertex triangle logo are registered trademarks of Vertex

More information

Cystic Fibrosis a) Diagnostic Dilemmas b) The New Problems. Dr Mark Rosenthal Royal Brompton Hospital London

Cystic Fibrosis a) Diagnostic Dilemmas b) The New Problems. Dr Mark Rosenthal Royal Brompton Hospital London Cystic Fibrosis a) Diagnostic Dilemmas b) The New Problems Dr Mark Rosenthal Royal Brompton Hospital London So what exactly is CF? A genetic diagnosis An electrolyte diagnosis An electrical diagnosis A

More information

IVF Michigan, Rochester Hills, Michigan, and Reproductive Genetics Institute, Chicago, Illinois

IVF Michigan, Rochester Hills, Michigan, and Reproductive Genetics Institute, Chicago, Illinois FERTILITY AND STERILITY VOL. 80, NO. 4, OCTOBER 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. CASE REPORTS Preimplantation

More information

Atypical cystic fibrosis: from the genetic causes to current and future treatments

Atypical cystic fibrosis: from the genetic causes to current and future treatments Boston University OpenBU Theses & Dissertations http://open.bu.edu Boston University Theses & Dissertations 2016 Atypical cystic fibrosis: from the genetic causes to current and future treatments Quinn,

More information

article May/June 2004 Vol. 6 No. 3

article May/June 2004 Vol. 6 No. 3 article May/June 2004 Vol. 6 No. 3 Cystic fibrosis screening: Lessons learned from the first 320,000 patients Charles M. Strom, MD, PhD, Beryl Crossley, MD, Joy B. Redman, MS, Arlene Buller, PhD, Franklin

More information

Respiratory Pharmacology: Treatment of Cystic Fibrosis

Respiratory Pharmacology: Treatment of Cystic Fibrosis Respiratory Pharmacology: Treatment of Cystic Fibrosis Dr. Tillie-Louise Hackett Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Associate Head, Centre of Heart

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Cystic Fibrosis Transmembrane Page 1 of 11 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Prime Therapeutics

More information

INFLAMMATION OF THE SINUS EPITHElium

INFLAMMATION OF THE SINUS EPITHElium PRELIMINARY COMMUNICATION Mutation in the Gene Responsible for Cystic Fibrosis and Predisposition to Chronic Rhinosinusitis in the General Population XinJing Wang, MD, PhD Birgitta Moylan Donald A. Leopold,

More information

What is Cystic Fibrosis? CYSTIC FIBROSIS. Genetics of CF

What is Cystic Fibrosis? CYSTIC FIBROSIS. Genetics of CF What is Cystic Fibrosis? CYSTIC FIBROSIS Lynne M. Quittell, M.D. Director, CF Center Columbia University Chronic, progressive and life limiting autosomal recessive genetic disease characterized by chronic

More information

Marita Gilljam, MD; Lynda Ellis, RN; Mary Corey, PhD; Julian Zielenski, PhD; Peter Durie, MD; and D. Elizabeth Tullis, MD, FCCP

Marita Gilljam, MD; Lynda Ellis, RN; Mary Corey, PhD; Julian Zielenski, PhD; Peter Durie, MD; and D. Elizabeth Tullis, MD, FCCP Clinical Manifestations of Cystic Fibrosis Among Patients With Diagnosis in Adulthood* Marita Gilljam, MD; Lynda Ellis, RN; Mary Corey, PhD; Julian Zielenski, PhD; Peter Durie, MD; and D. Elizabeth Tullis,

More information

CFTR Genotype as a Predictor of Prognosis in Cystic Fibrosis*

CFTR Genotype as a Predictor of Prognosis in Cystic Fibrosis* Original Research CYSTIC FIBROSIS CFTR Genotype as a Predictor of Prognosis in Cystic Fibrosis* Edward F. McKone, MD, MS; Christopher H. Goss, MD, MS, FCCP; and Moira L. Aitken, MD, FCCP Study rationale:

More information

Nasal potential difference measurements in patients with atypical cystic fibrosis

Nasal potential difference measurements in patients with atypical cystic fibrosis Eur Respir J 21; 17: 128 1215 Printed in UK all rights reserved Copyright #ERS Journals Ltd 21 European Respiratory Journal ISSN 93-1936 Nasal potential difference measurements in patients with atypical

More information

T he cystic fibrosis transmembrane conductance regulator

T he cystic fibrosis transmembrane conductance regulator 971 RESPIRATORY PHYSIOLOGY Nasal airway ion transport is linked to the cystic fibrosis phenotype in adult patients I Fajac, D Hubert, D Guillemot, I Honoré, T Bienvenu, F Volter, J Dall Ava-Santucci, D

More information

Title: Lack of correlation between pulmonary disease and CFTR dysfunction in cystic fibrosis -- the case of 3791delC

Title: Lack of correlation between pulmonary disease and CFTR dysfunction in cystic fibrosis -- the case of 3791delC Author's response to reviews Title: Lack of correlation between pulmonary disease and CFTR dysfunction in cystic fibrosis -- the case of 3791delC Authors: Hara Levy (hlevy@mcw.edu) Carolyn L. Cannon (cannon_c@kids.wustl.edu)

More information

Cystic fibrosis and infertility caused by congenital bilateral absence of the vas deferens and related clinical entities

Cystic fibrosis and infertility caused by congenital bilateral absence of the vas deferens and related clinical entities Cystic fibrosis and infertility caused by congenital bilateral absence of the vas deferens and related clinical entities Willy Lissens ljs, Bernard Mercier 2, Herman Tournaye 3, Maryse Bonduelle 1, Claude

More information

Lung function and disease severity in cystic fibrosis patients heterozygous for p.arg117his

Lung function and disease severity in cystic fibrosis patients heterozygous for p.arg117his Lung function and disease severity in cystic fibrosis patients heterozygous for p.arg117his Shteinberg, M., Downey, D. G., Beattie, D., McCaughan, J., Reid, A., Stein, N., & Elborn, J. S. (2017). Lung

More information

PULMONARY SURFACTANT, ALPHA 1 ANTITRYPSIN INHIBITOR DEFICIENCY, AND CYSTIC FIBROSIS DR. NABIL BASHIR BIOCHEMISTRY/RESPIRATORY SYSTEM

PULMONARY SURFACTANT, ALPHA 1 ANTITRYPSIN INHIBITOR DEFICIENCY, AND CYSTIC FIBROSIS DR. NABIL BASHIR BIOCHEMISTRY/RESPIRATORY SYSTEM PULMONARY SURFACTANT, ALPHA 1 ANTITRYPSIN INHIBITOR DEFICIENCY, AND CYSTIC FIBROSIS DR. NABIL BASHIR BIOCHEMISTRY/RESPIRATORY SYSTEM Pulmonary surfactant Pulmonary surfactant is (phospholipoprotein) complex

More information

Cystic fibrosis: terminology and diagnostic algorithms

Cystic fibrosis: terminology and diagnostic algorithms 627 OCCASIONAL REVIEW Cystic fibrosis: terminology and diagnostic algorithms K De Boeck, M Wilschanski, C Castellani, C Taylor, H Cuppens, J Dodge, M Sinaasappel, on behalf of the Diagnostic Working Group...

More information

A Genetic Approach to the Treatment of Cystic Fibrosis

A Genetic Approach to the Treatment of Cystic Fibrosis A Genetic Approach to the Treatment of Cystic Fibrosis Peter Mueller, PhD Chief Scientific Officer and Executive Vice President Global Research and Development Vertex Pharmaceuticals, Incorporated March

More information

What is the inheritance pattern (e.g., autosomal, sex-linked, dominant, recessive, etc.)?

What is the inheritance pattern (e.g., autosomal, sex-linked, dominant, recessive, etc.)? Module I: Introduction to the disease Give a brief introduction to the disease, considering the following: the symptoms that define the syndrome, the range of phenotypes exhibited by individuals with the

More information

Symposium: Genetic aspects of male (in)fertility

Symposium: Genetic aspects of male (in)fertility RBMOnline - Vol 10. No 1. 2005 14-41 Reproductive BioMedicine Online; www.rbmonline.com/article/1507 on web 23 November 2004 Symposium: Genetic aspects of male (in)fertility Molecular pathology of the

More information

Disclosures. Advances in the Management of Cystic Fibrosis: A Closer Look at the Roles of CFTR Modulation Therapy 10/28/2016

Disclosures. Advances in the Management of Cystic Fibrosis: A Closer Look at the Roles of CFTR Modulation Therapy 10/28/2016 Advances in the Management of Cystic Fibrosis: A Closer Look at the Roles of CFTR Modulation Therapy Susanna A McColley, MD Associate Chief Research Officer Stanley Manne Children s Research Institute

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Cystic Fibrosis Transmembrane Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Prime Therapeutics

More information

C hronic pancreatitis is a continuing or relapsing inflammatory

C hronic pancreatitis is a continuing or relapsing inflammatory 1456 PANCREATITIS Complete cystic fibrosis transmembrane conductance regulator gene sequencing in patients with idiopathic chronic pancreatitis and controls F U Weiss, P Simon, N Bogdanova, J Mayerle,

More information

SALSA MLPA KIT P060-B2 SMA

SALSA MLPA KIT P060-B2 SMA SALSA MLPA KIT P6-B2 SMA Lot 111, 511: As compared to the previous version B1 (lot 11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). Please note that, in contrast to the

More information

Supplemental Data: Detailed Characteristics of Patients with MKRN3. Patient 1 was born after an uneventful pregnancy. She presented in our

Supplemental Data: Detailed Characteristics of Patients with MKRN3. Patient 1 was born after an uneventful pregnancy. She presented in our 1 2 Supplemental Data: Detailed Characteristics of Patients with MKRN3 Mutations 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Patient 1 was born after an uneventful pregnancy. She presented

More information

MRC-Holland MLPA. Description version 19;

MRC-Holland MLPA. Description version 19; SALSA MLPA probemix P6-B2 SMA Lot B2-712, B2-312, B2-111, B2-511: As compared to the previous version B1 (lot B1-11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). SPINAL

More information

IVACAFTOR THE ISRAELI EXPERIENCE ADI DAGAN MD THE ISRAELI CF CENTER SHEBA MEDICAL CENTER, TEL-HASHOMER

IVACAFTOR THE ISRAELI EXPERIENCE ADI DAGAN MD THE ISRAELI CF CENTER SHEBA MEDICAL CENTER, TEL-HASHOMER IVACAFTOR THE ISRAELI EXPERIENCE ADI DAGAN MD THE ISRAELI CF CENTER SHEBA MEDICAL CENTER, TEL-HASHOMER February 21, 2014 U.S. Food and Drug Administration Approves KALYDECO (ivacaftor) for Use in Eight

More information

Mutation frequency of cystic fibrosis transmembrane regulator is not increased in oligozoospermic male candidates for intracytoplasmic sperm injection

Mutation frequency of cystic fibrosis transmembrane regulator is not increased in oligozoospermic male candidates for intracytoplasmic sperm injection FERTILITY AND STERILITY VOL. 69, NO. 5, MAY 1998 Copyright 1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Mutation frequency of

More information

6.2.1 Exocrine pancreatic insufficiency

6.2.1 Exocrine pancreatic insufficiency 6.2.1 Exocrine pancreatic insufficiency Authors: Jean Louis Frossard, Alain Sauty 1. INTRODUCTION Exocrine pancreatic insufficiency is a biological and clinical condition that is characterized by a progressive

More information

Most severely affected will be the probe for exon 15. Please keep an eye on the D-fragments (especially the 96 nt fragment).

Most severely affected will be the probe for exon 15. Please keep an eye on the D-fragments (especially the 96 nt fragment). SALSA MLPA probemix P343-C3 Autism-1 Lot C3-1016. As compared to version C2 (lot C2-0312) five reference probes have been replaced, one reference probe added and several lengths have been adjusted. Warning:

More information

Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations

Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations 2000 Oxford University Press Human Molecular Genetics, 2000, Vol. 9, No. 12 1771 1778 Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations

More information

Cystic Fibrosis Foundation Patient Registry 2013

Cystic Fibrosis Foundation Patient Registry 2013 5/9/2015 Targeting CFTR to Treat Cystic Fibrosis: Small Molecule Therapy Mary Ellen Kleinhenz, MD Director, UCSF Adult Cystic Fibrosis Program Professor of Medicine UCSF Division of Pulmonary, Critical

More information

A Quick Guide to the G A. Mutation CFTR SCIENCE

A Quick Guide to the G A. Mutation CFTR SCIENCE A Quick Guide to the 1717-1G A Mutation FR SIENE 2016 Vertex Pharmaceuticals Incorporated VXR-HQ-02-00045a(1) 03/2016 Loss of FR activity is the underlying cause of cystic fibrosis (F) 1 Spectrum of Phenotypes

More information

CONGENITAL bilateral absence of the vas deferens

CONGENITAL bilateral absence of the vas deferens Vol. 33 No. MUTATIONS IN THE CYSTIC FIBROSIS GENE AND ABSENCE OF THE VAS DEFERENS 475 MUTATIONS IN THE CYSTIC FIBROSIS GENE IN PATIENTS WITH CONGENITAL ABSENCE OF THE VAS DEFERENS MIGUEL CHILLÓN, PH.D.,

More information

CFTR mutations and IVS8-5T variant in newborns with hypertrypsinaemia and normal sweat test

CFTR mutations and IVS8-5T variant in newborns with hypertrypsinaemia and normal sweat test J7Med Genet 1997;34:297-301 Cystic Fibrosis Centre, Ospedale Civile Maggiore, Piazzale Stefani, 37126 Verona, Italy C Castellani A Bonizzato G Mastella Correspondence to: Dr Castellani. Received 25 June

More information

Chronic pancreatitis and cystic fibrosis

Chronic pancreatitis and cystic fibrosis ii31 PAPER Chronic pancreatitis and cystic fibrosis H Witt... Recent discoveries of trypsinogen and trypsin inhibitor mutations in patients with chronic pancreatitis (CP) support the hypothesis that an

More information

Characterizing aggressiveness and predicting future progression of CF lung disease

Characterizing aggressiveness and predicting future progression of CF lung disease Journal of Cystic Fibrosis Volume 8 Suppl 1 (2009) S15 S19 www.elsevier.com/locate/jcf Characterizing aggressiveness and predicting future progression of CF lung disease Michael W. Konstan a, *, Jeffrey

More information

Key Points: References: Canadian data from the Canadian Cystic Fibrosis Registry 2015 Annual Report normal

Key Points: References: Canadian data from the Canadian Cystic Fibrosis Registry 2015 Annual Report normal 1 2 3 Cystic fibrosis is a rare life-long genetic disease that affects approximately 4,000 people in Canada and about 70,000 worldwide regardless of race or ethnicity but is more common in Caucasians 1,2

More information

We describe a novel student course in membrane physiology in which

We describe a novel student course in membrane physiology in which MEASUREMENT OF HUMAN NASAL POTENTIAL DIFFERENCE TO TEACH THE THEORY OF TRANSEPITHELIAL FLUID TRANSPORT Ulrich Kersting, 1 Albrecht Schwab, 2 and Alexandra Hebestreit 3 1 Institute of Clinical Biochemistry

More information

Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis

Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis Federico Goodsaid Vice President Strategic Regulatory Intelligence Vertex Pharmaceuticals Is there

More information

Cystic fibrosis: terminology and diagnostic algorithms

Cystic fibrosis: terminology and diagnostic algorithms Thorax Online First, published on December 29, 2005 as 10.1136/thx.2005.043539 1 Cystic fibrosis: terminology and diagnostic algorithms De Boeck K 1, Wilschanski M 2, Castellani C 3, Taylor C 4, Cuppens

More information

Pulmonary Function and Clinical Observations in Men With Congenital Bilateral Absence of the Vas Deferens*

Pulmonary Function and Clinical Observations in Men With Congenital Bilateral Absence of the Vas Deferens* Pulmonary Function and Clinical Observations in Men With Congenital Bilateral Absence of the Vas Deferens* Andrew A. Colin, MD; Susan M. Sawyer, MBBS, MD; John E. Mickle, BA; Robert D. Oates, MD; Aubrey

More information

SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY.

SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY. SAMPLE REPORT SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY. RESULTS SNP Array Copy Number Variations Result: LOSS,

More information

NON-CF BRONCHIECTASIS IN ADULTS

NON-CF BRONCHIECTASIS IN ADULTS Séminaire de Pathologie Infectieuse Jeudi 25 juin 2008 Cliniques Universitaires UCL de Mont-Godinne, Yvoir NON-CF BRONCHIECTASIS IN ADULTS Dr Robert Wilson Royal Brompton Hospital, London, UK Aetiology

More information

Mai ElMallah,MD Updates in Pediatric Pulmonary Care XII: An Interdisciplinary Program April 13, 2012

Mai ElMallah,MD Updates in Pediatric Pulmonary Care XII: An Interdisciplinary Program April 13, 2012 Mai ElMallah,MD Updates in Pediatric Pulmonary Care XII: An Interdisciplinary Program April 13, 2012 Recognize the importance of Pulmonary Function Testing in Cystic Fibrosis Be aware of different types

More information

Human Genetic Diseases. AP Biology

Human Genetic Diseases. AP Biology Human Genetic Diseases 1 2 2006-2007 3 4 5 6 Pedigree analysis Pedigree analysis reveals Mendelian patterns in human inheritance data mapped on a family tree = male = female = male w/ trait = female w/

More information

GENETIC TESTING: IN WHOM AND WHEN

GENETIC TESTING: IN WHOM AND WHEN GENETIC TESTING: IN WHOM AND WHEN Robert D Oates, M.D. Boston University School of Medicine My background in this field I was the first to link Cystic Fibrosis Mutations with Congenital Absence of the

More information

Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data

Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data See Editorial, p 575 < Supplementary figures are published online only. To view these files please visit the journal online (http://thorax.bmj. com). 1 Cystic Fibrosis Centre, Department of Pediatric Pulmonology

More information

Article Molecular analysis of mutations and polymorphisms in the CFTR gene in male infertility

Article Molecular analysis of mutations and polymorphisms in the CFTR gene in male infertility RBMOnline - Vol 17 No 1. 2008 27-35 Reproductive BioMedicine Online; www.rbmonline.com/article/3229 on web 10 May 2008 Article Molecular analysis of mutations and polymorphisms in the CFTR gene in male

More information

Focus on Cystic Fibrosis. Cystic Fibrosis. Cystic Fibrosis

Focus on Cystic Fibrosis. Cystic Fibrosis. Cystic Fibrosis Focus on (Relates to Chapter 29, Nursing Management: Obstructive Pulmonary Diseases, in the textbook) Copyright 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Autosomal recessive, multisystem

More information

PRADER WILLI/ANGELMAN

PRADER WILLI/ANGELMAN SALSA MS-MLPA probemix ME028-B2 PRADER WILLI/ANGELMAN Lot B2-0811: As compared to version B1 (lot B1-0609, B1-1108), the 88 and 96 nt control fragments have been replaced (QDX2). PRADER-WILLI SYNDROME

More information

FACTS ABOUT. Cystic Fibrosis. What Is Cystic Fibrosis. What Are the Signs and Symptoms of CF?

FACTS ABOUT. Cystic Fibrosis. What Is Cystic Fibrosis. What Are the Signs and Symptoms of CF? FACTS ABOUT Cystic Fibrosis What Is Cystic Fibrosis Cystic fibrosis (CF) is a chronic, progressive, and frequently fatal genetic (inherited) disease of the body s mucus glands. CF primarily affects the

More information

150 mm HCO How Does the Pancreas Do It? Clues from Computer Modelling of the Duct Cell

150 mm HCO How Does the Pancreas Do It? Clues from Computer Modelling of the Duct Cell JOP. J. Pancreas (Online) 2001; 2(4 Suppl):198202. 150 mm How Does the Pancreas Do It? Clues from Computer Modelling of the Duct Cell Yoshiro Sohma 1, Michael A Gray 2, Yusuke Imai 1, Barry E Argent 2

More information

Goals Basic defect Pathophysiology Clinical i l signs and symptoms Therapy

Goals Basic defect Pathophysiology Clinical i l signs and symptoms Therapy CYSTIC FIBROSIS Lynne M. Quittell, M.D. Director, CF Center Columbia University Goals Basic defect Pathophysiology Clinical i l signs and symptoms Therapy What is Cystic Fibrosis? Chronic, progressive

More information

Atypical 5 Splice Sites Cause CFTR Exon 9 To Be Vulnerable to Skipping

Atypical 5 Splice Sites Cause CFTR Exon 9 To Be Vulnerable to Skipping Am. J. Hum. Genet. 71:294 303, 2002 Atypical 5 Splice Sites Cause CFTR Exon 9 To Be Vulnerable to Skipping Timothy W. Hefferon, 1,2 Fiona C. Broackes-Carter, 3 Ann Harris, 3 and Garry R. Cutting 1 1 McKusick-Nathans

More information

You Can Observe a Lot By Just Watching. Wayne J. Morgan, MD, CM

You Can Observe a Lot By Just Watching. Wayne J. Morgan, MD, CM You Can Observe a Lot By Just Watching Wayne J. Morgan, MD, CM Disclosures Genentech Epidemiological Study of Cystic Fibrosis, Scientific Advisory Group CF Foundation Data Safety Monitoring Board Registry/Comparative

More information

Genome - Wide Linkage Mapping

Genome - Wide Linkage Mapping Biological Sciences Initiative HHMI Genome - Wide Linkage Mapping Introduction This activity is based on the work of Dr. Christine Seidman et al that was published in Circulation, 1998, vol 97, pgs 2043-2048.

More information

High morbidity and mortality in cystic fibrosis patients compound heterozygous for 3905insT and DF508

High morbidity and mortality in cystic fibrosis patients compound heterozygous for 3905insT and DF508 Eur Respir J 21; 17: 1181 1186 Printed in UK all rights reserved Copyright #ERS Journals Ltd 21 European Respiratory Journal ISSN 93-1936 High morbidity and mortality in cystic fibrosis patients compound

More information

Human Genetic Diseases. AP Biology

Human Genetic Diseases. AP Biology Human Genetic Diseases 1 3 4 2 5 2006-2007 6 Pedigree analysis n Pedigree analysis reveals Mendelian patterns in human inheritance u data mapped on a family tree = male = female = male w/ trait = female

More information

Table S1. Primers and PCR protocols for mutation screening of MN1, NF2, KREMEN1 and ZNRF3.

Table S1. Primers and PCR protocols for mutation screening of MN1, NF2, KREMEN1 and ZNRF3. Table S1. Primers and PCR protocols for mutation screening of MN1, NF2, KREMEN1 and ZNRF3. MN1 (Accession No. NM_002430) MN1-1514F 5 -GGCTGTCATGCCCTATTGAT Exon 1 MN1-1882R 5 -CTGGTGGGGATGATGACTTC Exon

More information

Cystic Fibrosis. Parkland College. Monica Rahman Parkland College. Recommended Citation

Cystic Fibrosis. Parkland College. Monica Rahman Parkland College. Recommended Citation Parkland College A with Honors Projects Honors Program 2013 Cystic Fibrosis Monica Rahman Parkland College Recommended Citation Rahman, Monica, "Cystic Fibrosis" (2013). A with Honors Projects. 98. http://spark.parkland.edu/ah/98

More information

Cystic fibrosis: From childhood to adulthood. Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel

Cystic fibrosis: From childhood to adulthood. Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel Cystic fibrosis: From childhood to adulthood Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel Vas deference H 2 O Cl - Na + H 2 O Na + Cl - Cl - Cl -

More information

MRC-Holland MLPA. Description version 52; 22 July 2015

MRC-Holland MLPA. Description version 52; 22 July 2015 SALSA MS-MLPA probemix ME028-B2 Prader-Willi/Angelman Lot B2-0413, lot B2-0811. As compared to version B1 (lot B1-0609), the control fragments have been replaced (QDX2). PRADER-WILLI SYNDROME (PWS) and

More information

Cystic Fibrosis Diagnosis and Treatment

Cystic Fibrosis Diagnosis and Treatment Cystic Fibrosis Diagnosis and Treatment Financial Disclosures Personal financial relationships with commercial interests relevant to medicine, within the past 3 years: NJH site PI for AstraZeneca. As faculty

More information

Mutation spectrum of the CFTR gene in Taiwanese patients with congenital bilateral absence of the vas deferens

Mutation spectrum of the CFTR gene in Taiwanese patients with congenital bilateral absence of the vas deferens Human Reproduction Vol.20, No.9 pp. 2470 2475, 2005 Advance Access publication May 19, 2005 doi:10.1093/humrep/dei077 Mutation spectrum of the CFTR gene in Taiwanese patients with congenital bilateral

More information

TEST INFORMATION Test: CarrierMap GEN (Genotyping) Panel: CarrierMap Expanded Diseases Tested: 311 Genes Tested: 299 Mutations Tested: 2647

TEST INFORMATION Test: CarrierMap GEN (Genotyping) Panel: CarrierMap Expanded Diseases Tested: 311 Genes Tested: 299 Mutations Tested: 2647 Ordering Practice Jane Smith John Smith Practice Code: 675 Miller MD 374 Broadway New York, NY 10000 Physician: Dr. Frank Miller Report Generated: 2016-02-03 DOB: 1973-02-19 Gender: Female Ethnicity: European

More information

Transformational Treatments. PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs

Transformational Treatments. PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs Transformational Treatments PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs Symptom-based CF Therapies 45 Median Predicted Survival Age of US Patients with Cystic Fibrosis 41

More information

Pediatrics Grand Rounds 18 Sept University of Texas Health Science Center. + Disclosure. + Learning Objectives.

Pediatrics Grand Rounds 18 Sept University of Texas Health Science Center. + Disclosure. + Learning Objectives. Disclosure Dr Donna Willey Courand receives research support from Cystic Fibrosis Therapeutics The Cystic Fibrosis Foundation Children with Special Health Care Needs Cystic Fibrosis 05: Improving Survival

More information

NON-CYSTIC FIBROSIS BRONCHIECTASIS

NON-CYSTIC FIBROSIS BRONCHIECTASIS NON-CYSTIC FIBROSIS BRONCHIECTASIS MARK L. METERSKY, MD PROFESSOR OF MEDICINE UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE FARMINGTON, CT Mark Metersky, MD, FCCP, FACP is a Professor of Medicine at the

More information

Pediatrics Grand Rounds 13 November University of Texas Health Science Center at San Antonio. Learning Objectives

Pediatrics Grand Rounds 13 November University of Texas Health Science Center at San Antonio. Learning Objectives Nationwide Newborn Screening for Cystic Fibrosis: Finally Creating an Opportunity for All Patients to Have Better Outcomes Philip M Farrell, MD, PhD* University of Wisconsin-Madison *No disclosures other

More information

Cystic Fibrosis the future

Cystic Fibrosis the future Cystic Fibrosis the future Pathophysiologic cascade Abnormal Gene Abnormal CFTR Therapy Gene replacement Protein replacement Gene read through therapy Abnormal sodium chloride & water movement through

More information

Bronchiectasis Domiciliary treatment. Prof. Adam Hill Royal Infirmary and University of Edinburgh

Bronchiectasis Domiciliary treatment. Prof. Adam Hill Royal Infirmary and University of Edinburgh Bronchiectasis Domiciliary treatment Prof. Adam Hill Royal Infirmary and University of Edinburgh Plan of talk Background of bronchiectasis Who requires IV antibiotics Domiciliary treatment Results to date.

More information

Role of Paired Box9 (PAX9) (rs ) and Muscle Segment Homeobox1 (MSX1) (581C>T) Gene Polymorphisms in Tooth Agenesis

Role of Paired Box9 (PAX9) (rs ) and Muscle Segment Homeobox1 (MSX1) (581C>T) Gene Polymorphisms in Tooth Agenesis EC Dental Science Special Issue - 2017 Role of Paired Box9 (PAX9) (rs2073245) and Muscle Segment Homeobox1 (MSX1) (581C>T) Gene Polymorphisms in Tooth Agenesis Research Article Dr. Sonam Sethi 1, Dr. Anmol

More information

Michael Wilschanski Pediatric Gastroenterology, Hadassah Medical Organization Jerusalem, Israel

Michael Wilschanski Pediatric Gastroenterology, Hadassah Medical Organization Jerusalem, Israel Recurrent Acute Pancreatitis in Israeli, Children Michael Wilschanski Pediatric Gastroenterology, Hadassah Medical Organization Jerusalem, Israel ISPGHAN EILAT FEBRUARY RY 2013 Etiologies of recurrent/chronic

More information

Human Genetic Diseases (Ch. 15)

Human Genetic Diseases (Ch. 15) Human Genetic Diseases (Ch. 15) 1 2 2006-2007 3 4 5 6 Genetic counseling Pedigrees can help us understand the past & predict the future Thousands of genetic disorders are inherited as simple recessive

More information

Single Gene (Monogenic) Disorders. Mendelian Inheritance: Definitions. Mendelian Inheritance: Definitions

Single Gene (Monogenic) Disorders. Mendelian Inheritance: Definitions. Mendelian Inheritance: Definitions Single Gene (Monogenic) Disorders Mendelian Inheritance: Definitions A genetic locus is a specific position or location on a chromosome. Frequently, locus is used to refer to a specific gene. Alleles are

More information

Formal Genetics of Humans: Modes of Inheritance. Dr. S Hosseini-Asl

Formal Genetics of Humans: Modes of Inheritance. Dr. S Hosseini-Asl Formal Genetics of Humans: Modes of Inheritance Dr. S Hosseini-Asl 1 Autosomal dominant (AD) a: Wild type (Wt) allele A: Mutant allele aa: Normal phenotype Aa: Affected (heterozygous) AA: Affected (homozygous)

More information

Chronic suppurative lung disease in adults

Chronic suppurative lung disease in adults Case Report Chronic suppurative lung disease in adults Mark L. Metersky 1, Antranik Mangardich 2 1 Division of Pulmonary and Critical Care Medicine, University of Connecticut School of Medicine, Farmington,

More information

Basic Definitions. Dr. Mohammed Hussein Assi MBChB MSc DCH (UK) MRCPCH

Basic Definitions. Dr. Mohammed Hussein Assi MBChB MSc DCH (UK) MRCPCH Basic Definitions Chromosomes There are two types of chromosomes: autosomes (1-22) and sex chromosomes (X & Y). Humans are composed of two groups of cells: Gametes. Ova and sperm cells, which are haploid,

More information

Pharmacy Policy Bulletin

Pharmacy Policy Bulletin Pharmacy Policy Bulletin Title: Policy #: Cystic Fibrosis Agents (Kalydeco, Orkambi ) Rx.01.117 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product

More information